Foresite Capital Fund IV, L.P. 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 3:13 pm Sale | 2021-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV, L.P. | 0 0.000% | -1,412,705 (Position Closed) | Filing |
| 2021-02-16 10:56 am Sale | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV, L.P. | 1,412,705 6.100% | -15,366 (-1.08%) | Filing |